BeyondSpring (BYSI) Set to Release Earnings on Thursday

BeyondSpring (NASDAQ:BYSI) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.54) per share and revenue of $8.77 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.52.

BeyondSpring Stock Performance

Shares of BYSI opened at $0.62 on Tuesday. The company has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $1.24. The firm has a market capitalization of $25.37 million, a P/E ratio of -5.14 and a beta of -0.12. BeyondSpring has a 52 week low of $0.42 and a 52 week high of $2.44.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

About BeyondSpring

BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects.

Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment.